The hypolipidaemic effect of EPA is potentiated by 2- and 3-methylation.
Vaagenes
H
H
Department of Clinical Biochemistry, University of Bergen, Haukeland Hospital, Norway.
Madsen
L
L
Dyrøy
E
E
Frøyland
L
L
Willumsen
N
N
Berge
R K
RK
D042962:Acyl-CoA Oxidase; D000284:Administration, Oral; D000818:Animals; D002784:Cholesterol / Q000097:blood; D015118:Eicosapentaenoic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology*; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D050356:Lipid Metabolism; D008055:Lipids / Q000097:blood; D008745:Methylation; D008930:Mitochondria, Liver / Q000187:drug effects / Q000378:metabolism*; D010088:Oxidoreductases / Q000235:genetics / Q000378:metabolism; D010743:Phospholipids / Q000097:blood; D051381:Rats; D014280:Triglycerides / Q000097:blood
D000960:Hypolipidemic Agents; D008055:Lipids; D010743:Phospholipids; D014280:Triglycerides; D002784:Cholesterol; D015118:Eicosapentaenoic Acid; D010088:Oxidoreductases; D042962:Acyl-CoA Oxidase